Quay Pharma Completes FDA Pre-Qualification Inspection
The company announced that its facilities and laboratories have completed FDA pre-qualification inspection.
On July 19, 2016, Quay Pharma announced that its laboratories and manufacturing facilities have completed FDA pre-qualification inspection. The inspection confirmed that the company’s systems are GMP compliant and no deficiencies were identified. Quay recently invested £3 million (approximately $3.93 million) in GMP manufacturing suites. The company also recently received a Commercial License from the Medicines and Healthcare Products Regulatory Agency.
Source: Quay Pharma
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
